Abstract
BACKGROUND Alzheimer’s disease-related biomarkers detect pathology years before symptoms emerge, when disease-modifying therapies might be most beneficial. Remote cognitive testing provides a means of assessing early changes. We explored the relationship between neurodegenerative biomarkers and cognition in cognitively normal individuals.
METHODS We remotely deployed 13 computerised Cognitron tasks in 255 Insight 46 participants. We generated whole brain, hippocampal, and white matter hyperintensity volumes at ages 69-71, rates of change over two-years, amyloid load and positivity. We examined the relationship between Cognitron, biomarkers, and standard neuropsychological tests.
RESULTS Slower response time on a delayed recognition task predicted amyloid positivity (OR=1.79,CI:1.15, 2.95). Brain and hippocampal atrophy rates correlated with poorer visuospatial performance (b=-0.42, CI:-0.80, -0.05) and accuracy on immediate recognition (b=-0.01, CI:-0.01, -0.001), respectively. Standard tests correlated with Cognitron composites (rho=0.43, p<0.001).
DISCUSSION Remote computerised testing correlates with standard supervised assessments and holds potential for studying early cognitive changes associated with neurodegeneration.
Competing Interest Statement
AH is owner/director of H2 Cognitive Designs Ltd and Future Cognition Ltd, which produce online assessment technology and provide online survey data collection for third parties. PH is founder and director of H2 Cognitive Designs LTD, which develops and markets online cognitive tests. WT is an employee of H2 Cognitive Designs LTD. PM is lead for an NIHR-funded trial with drug/placebo provided by Takeda Pharmaceuticals and sits on the Data Monitoring Committee for a trial being carried out by Johnson and Johnson.
Funding Statement
Insight 46 is funded by grants from Alzheimer's Research UK (ARUK-PG2014-1946, ARUK- PG2017-1946), Alzheimer's Association (SG-666374-UK BIRTH COHORT), the Medical Research Council Dementias Platform UK (CSUB19166), The Wolfson Foundation (PR/ylr/18575), The Medical Research Council (MC_UU_10019/1, MC_UU_10019/3), and Brain Research Trust (UCC14191). Florbetapir amyloid tracer was provided in kind by AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) who had no part in the design of the study. The funders of the study had no role in study design, data collection, analysis, interpretation, report writing, or in the decision to submit the article for publication. JMS acknowledges the support of University College London Hospitals Biomedical Research Centre. MR is funded by the Medical Research Council (MC_UU_00019/1 and 3). VG is supported by the Medical Research Council, MR/W00710X/1. AW and MP are funded by the Medical Research Council (MC_UU_00019/1). TP is supported by a National Institute Healthcare Research (NIHR) lectureship. KL has nothing to disclose. MDG is employed as research technician by Imperial College London. PM receives research funding from Lifearc, NIHR, MRC, Dementia Platforms UK, Alzheimer's Research UK, the Football Association, FIFA and Alzheimer's Society. The study was also supported by the Biomedical Research Centre at Imperial College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the National Research Ethics Service Committee London (REC reference 19/LO/1774) and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data sharing is subject to application through the National Survey of Health and Development portal (https://nshd.mrc.ac.uk)
